Innate Immunotherapeutics Ltd Stock Australian S.E.
Equities
AU000000IIL6
Biotechnology & Medical Research
Sales 2022 | 1.98M 1.27M | Sales 2023 | 1.19M 763K | Capitalization | 16.49M 10.58M |
---|---|---|---|---|---|
Net income 2022 | -3M -1.92M | Net income 2023 | -6M -3.85M | EV / Sales 2022 | 7.87 x |
Net cash position 2022 | 12.51M 8.03M | Net cash position 2023 | 6.98M 4.48M | EV / Sales 2023 | 7.99 x |
P/E ratio 2022 |
-5.79
x | P/E ratio 2023 |
-2.64
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 56.37% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 00-05-30 | |
Tim Luscombe
DFI | Director of Finance/CFO | - | 23-09-24 |
Rhiannon Jones
COO | Chief Operating Officer | - | 21-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Cooke
SEC | Corporate Secretary | 62 | 13-10-10 |
Robert Peach
BRD | Director/Board Member | 68 | 15-09-01 |
Warwick Tong
CHM | Chairman | - | 18-05-03 |
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |